An open-label examine was completed in 2016 in the united kingdom to research the feasibility, safety and efficacy of psilocybin in treating patients with unipolar treatment-resistant depression with promising benefits; although the examine was tiny and concerned only twelve clients, seven of those people fulfilled formal criteria for remission a s